CE
Celularity Inc.
CELU · NASDAQ
$1.60 +15.94% (+$0.22)
1M -4.76%
Market Cap $39.9M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$2.23
39.4% upside
Current Price
$1.6
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CELU is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
90 /100
Cheap P/S 1.50x
P/E N/A
EV/EBITDA N/A
Growth
83 /100
Growing Rev. growth 13.88%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 76.04%
Net margin 345.44%
Op. margin 230.92%
Quality
4 /100
Poor ROIC 151.11%
ROA 85.45%
Asset turnover 0.25x
Debt
0 /100
High Current ratio 0.15x
Int. coverage -12.58x
Debt/Equity N/A
Stability
22 /100
Unstable Beta 0.54x
Rev. volatility 95.07%
EPS volatility 743.15%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CELU
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Robert Joseph Hariri
Employees
115
Headquarters
Florham Park
Upcoming events
13 NOV
Earnings
Upcoming earnings report